ReviewJournal of multidisciplinary healthcare2017
Sickle cell retinopathy: improving care with a multidisciplinary approach.
Review in Journal of multidisciplinary healthcare, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- EHA Guidelines on the management of children and adults with hemoglobin SC disease.HemaSphere · 2026Article
- Review
- Prevalence of ocular complications of sickle cell disease in children seen at a tertiary health facility in Southern Ghana.Journal of sickle cell disease · 2026Article
- Sickle cell retinopathy in pediatric patients: exploring correlations and predictive factors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Managing emotional and physical stress in sickle cell anemia: a review of effective strategies and approaches.Annals of medicine and surgery (2012) · 2025Review
- The role of long noncoding RNAs in ocular angiogenesis and vascular oculopathy.Cell & bioscience · 2024Review
- Risk factors associated with sickle cell retinopathy: findings from the Cooperative Study of Sickle Cell Disease.International journal of retina and vitreous · 2022Article
- A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers.Scientific reports · 2022Article
- Co-occurrence of sickle cell disease and oculocutaneous albinism in a Congolese patient: a case report.Journal of medical case reports · 2021Article
- Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence.Molecules (Basel, Switzerland) · 2021Article
- Quantification of intermittent retinal capillary perfusion in sickle cell disease.Biomedical optics express · 2021Article
- Surgical and Medical Perioperative Management of Sickle Cell Retinopathy: A Literature Review.International ophthalmology clinics · 2020Review
- Interocular asymmetry of foveal avascular zone morphology and parafoveal capillary density in sickle cell retinopathy.PloS one · 2020Article
- A review of the multifunctionality of angiopoietin-like 4 in eye disease.Bioscience reports · 2018Review
- Hemoglobin S/OCase reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell retinopathy (SCR) is the most representative ophthalmologic complication of sickle cell disease (SCD), a hemoglobinopathy affecting both adults and children. SCR presents a wide spectrum of manifestations and may even lead to irreversible vision loss if not properly diagnosed and treated at the earliest. Over the past decade, multidisciplinary research developments have focused upon systemic, genetic, and ocular risk factors of SCR, enabling the clinician to better diagnose and manage these patients. In addition, newer imaging and testing modalities, such as spectral domain-optical coherence tomography angiography, have resulted in the detection of subclinical retinopathy related to SCD. Innovative therapy includes intravitreal injection of an anti-vascular endothelial growth factor (eg, Lucentis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.